Cargando…

Growth rate of early-stage hepatocellular carcinoma in patients with chronic liver disease

BACKGROUND/AIMS: The goal of this study was to estimate the growth rate of hepatocellular carcinoma (HCC) and identify the host factors that significantly affect this rate. METHODS: Patients with early-stage HCC (n=175) who underwent two or more serial dynamic imaging studies without any anticancer...

Descripción completa

Detalles Bibliográficos
Autores principales: An, Chansik, Choi, Youn Ah, Choi, Dongil, Paik, Yong Han, Ahn, Sang Hoon, Kim, Myeong-Jin, Paik, Seung Woon, Han, Kwang-Hyub, Park, Mi-Suk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association for the Study of the Liver 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612289/
https://www.ncbi.nlm.nih.gov/pubmed/26523271
http://dx.doi.org/10.3350/cmh.2015.21.3.279
_version_ 1782396155389280256
author An, Chansik
Choi, Youn Ah
Choi, Dongil
Paik, Yong Han
Ahn, Sang Hoon
Kim, Myeong-Jin
Paik, Seung Woon
Han, Kwang-Hyub
Park, Mi-Suk
author_facet An, Chansik
Choi, Youn Ah
Choi, Dongil
Paik, Yong Han
Ahn, Sang Hoon
Kim, Myeong-Jin
Paik, Seung Woon
Han, Kwang-Hyub
Park, Mi-Suk
author_sort An, Chansik
collection PubMed
description BACKGROUND/AIMS: The goal of this study was to estimate the growth rate of hepatocellular carcinoma (HCC) and identify the host factors that significantly affect this rate. METHODS: Patients with early-stage HCC (n=175) who underwent two or more serial dynamic imaging studies without any anticancer treatment at two tertiary care hospitals in Korea were identified. For each patient, the tumor volume doubling time (TVDT) of HCC was calculated by comparing tumor volumes between serial imaging studies. Clinical and laboratory data were obtained from the medical records of the patients. RESULTS: The median TVDT was 85.7 days, with a range of 11 to 851.2 days. Multiple linear regression revealed that the initial tumor diameter (a tumor factor) and the etiology of chronic liver disease (a host factor) were significantly associated with the TVDT. The TVDT was shorter when the initial tumor diameter was smaller, and was shorter in HCC related to hepatitis B virus (HBV) infection than in HCC related to hepatitis C virus (HCV) infection (median, 76.8 days vs. 137.2 days; P=0.0234). CONCLUSIONS: The etiology of chronic liver disease is a host factor that may significantly affect the growth rate of early-stage HCC, since HBV-associated HCC grows faster than HCV-associated HCC.
format Online
Article
Text
id pubmed-4612289
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher The Korean Association for the Study of the Liver
record_format MEDLINE/PubMed
spelling pubmed-46122892015-10-30 Growth rate of early-stage hepatocellular carcinoma in patients with chronic liver disease An, Chansik Choi, Youn Ah Choi, Dongil Paik, Yong Han Ahn, Sang Hoon Kim, Myeong-Jin Paik, Seung Woon Han, Kwang-Hyub Park, Mi-Suk Clin Mol Hepatol Original Article BACKGROUND/AIMS: The goal of this study was to estimate the growth rate of hepatocellular carcinoma (HCC) and identify the host factors that significantly affect this rate. METHODS: Patients with early-stage HCC (n=175) who underwent two or more serial dynamic imaging studies without any anticancer treatment at two tertiary care hospitals in Korea were identified. For each patient, the tumor volume doubling time (TVDT) of HCC was calculated by comparing tumor volumes between serial imaging studies. Clinical and laboratory data were obtained from the medical records of the patients. RESULTS: The median TVDT was 85.7 days, with a range of 11 to 851.2 days. Multiple linear regression revealed that the initial tumor diameter (a tumor factor) and the etiology of chronic liver disease (a host factor) were significantly associated with the TVDT. The TVDT was shorter when the initial tumor diameter was smaller, and was shorter in HCC related to hepatitis B virus (HBV) infection than in HCC related to hepatitis C virus (HCV) infection (median, 76.8 days vs. 137.2 days; P=0.0234). CONCLUSIONS: The etiology of chronic liver disease is a host factor that may significantly affect the growth rate of early-stage HCC, since HBV-associated HCC grows faster than HCV-associated HCC. The Korean Association for the Study of the Liver 2015-09 2015-09-30 /pmc/articles/PMC4612289/ /pubmed/26523271 http://dx.doi.org/10.3350/cmh.2015.21.3.279 Text en Copyright © 2015 by The Korean Association for the Study of the Liver http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
An, Chansik
Choi, Youn Ah
Choi, Dongil
Paik, Yong Han
Ahn, Sang Hoon
Kim, Myeong-Jin
Paik, Seung Woon
Han, Kwang-Hyub
Park, Mi-Suk
Growth rate of early-stage hepatocellular carcinoma in patients with chronic liver disease
title Growth rate of early-stage hepatocellular carcinoma in patients with chronic liver disease
title_full Growth rate of early-stage hepatocellular carcinoma in patients with chronic liver disease
title_fullStr Growth rate of early-stage hepatocellular carcinoma in patients with chronic liver disease
title_full_unstemmed Growth rate of early-stage hepatocellular carcinoma in patients with chronic liver disease
title_short Growth rate of early-stage hepatocellular carcinoma in patients with chronic liver disease
title_sort growth rate of early-stage hepatocellular carcinoma in patients with chronic liver disease
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612289/
https://www.ncbi.nlm.nih.gov/pubmed/26523271
http://dx.doi.org/10.3350/cmh.2015.21.3.279
work_keys_str_mv AT anchansik growthrateofearlystagehepatocellularcarcinomainpatientswithchronicliverdisease
AT choiyounah growthrateofearlystagehepatocellularcarcinomainpatientswithchronicliverdisease
AT choidongil growthrateofearlystagehepatocellularcarcinomainpatientswithchronicliverdisease
AT paikyonghan growthrateofearlystagehepatocellularcarcinomainpatientswithchronicliverdisease
AT ahnsanghoon growthrateofearlystagehepatocellularcarcinomainpatientswithchronicliverdisease
AT kimmyeongjin growthrateofearlystagehepatocellularcarcinomainpatientswithchronicliverdisease
AT paikseungwoon growthrateofearlystagehepatocellularcarcinomainpatientswithchronicliverdisease
AT hankwanghyub growthrateofearlystagehepatocellularcarcinomainpatientswithchronicliverdisease
AT parkmisuk growthrateofearlystagehepatocellularcarcinomainpatientswithchronicliverdisease